NewcelX (NCEL) Notes Payables (2019 - 2024)

NewcelX (NCEL) posted quarterly Notes Payables of $201285.0 for Q2 2024, down 87.68% quarter-over-quarter from $1.6 million in Q4 2023.

NewcelX (NCEL) Notes Payables (2019 - 2024) Analysis & Trends

NewcelX (NCEL) has reported Notes Payables for 5 consecutive years, with $201285.0 the latest figure, recorded in Q2 2024.

In Q2 2024, Notes Payables changed N/A year-over-year to $201285.0; the TTM figure through Jun 2024 stood at $201285.0 (changed N/A YoY), while the FY2023 annual figure was $1.6 million, changed N/A from the prior year.
Notes Payables eased to $201285.0 in Q2 2024 per NCEL's latest filing, from $1.6 million in the prior quarter.
Across five years, Notes Payables topped out at $1.6 million in Q4 2023 and bottomed at $201285.0 in Q2 2024.
Historically, Notes Payables has averaged $695265.0 across 4 years, with a median of $473014.5 in 2020.
On a YoY basis, Notes Payables climbed as much as 9.56% in 2020 and fell as far as 9.56% in 2020.
NewcelX's Notes Payables stood at $591693.0 in 2020, then slumped by 40.11% to $354336.0 in 2022, then soared by 361.07% to $1.6 million in 2023, then tumbled by 87.68% to $201285.0 in 2024.
Business Quant data shows NCEL's Notes Payables at $201285.0 in Q2 2024, $1.6 million in Q4 2023, and $354336.0 in Q2 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.90 Bn	132.05 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	86.70 Bn	78.71 Bn	3.93 Bn
3	Argenx Se	65.73 Bn	60.55 Bn	1.37 Bn
4	Moderna	58.33 Bn	53.19 Bn	52.00 Mn
5	BeOne Medicines	42.16 Bn	37.07 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.72 Bn	28.42 Bn	992.69 Mn
7	BioNTech SE	28.27 Bn	9.88 Bn	668.28 Mn
8	Insmed	27.61 Bn	26.45 Bn	358.27 Mn
9	Royalty Pharma	27.25 Bn	26.41 Bn	-
10	NewcelX	12.65 Mn	10.45 Mn	-

Download Data